Nixdorf and colleagues designed and tested a biotin-directed AdCAR in combination with biotinylated anti-CD33, anti-human C-type lectin-like molecule-1 (CLL-1), or anti-CD123 AMs against acute myeloid leukemia (AML) cell lines and primary AML (pAML), both in vitro and in vivo. This evidence concerns the gene CLEC12A and acute myeloid leukemia.